This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other myotonic disorders (symptomatic, chondrodystrophic, pseudomyotonia, etc.)Other Myotonic Disorders

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G71.1 | Special Copayment Reduction: V012 | Registration validity period: 5 years
B. SynonymsMyotonic disorder (general), pseudomyotonia, symptomatic myotonia, chondrodystrophic myotonia, Schwartz-Jampel syndrome, drug-induced myotonia
C. Adult onsetLikelihood of first onset in adulthood varies — Schwartz-Jampel syndrome first presents in childhood; symptomatic (drug-induced) myotonia mainly occurs in adults after drug use.
1. HistoryGo to section
2. CausesGo to section
3. GeneticsGo to section
4. General epidemiologyGo to section
5. PathophysiologyGo to section
6. SymptomsGo to section
7. SignsGo to section
8. ScreeningGo to section
9. DiagnosisGo to section
10. TreatmentGo to section
11. PrognosisGo to section
12. PreventionGo to section
13. ReferencesGo to section

1. History

ICD-10 G71.1 'Other myotonic disorders' is a category that includes a heterogeneous clinical group not falling under clearly classified myotonic diseases such as DM1, DM2, myotonia congenita (CLCN1), paramyotonia (SCN4A) and neuromyotonia (Isaacs). Schwartz-Jampel syndrome (SJS), one of the representative diseases in this group, entered the medical literature in 1962 when the American ophthalmologist Oscar Schwartz and neurologist Robert S. Jampel first described a syndrome of skeletal abnormalities with muscle stiffness. SJS is also called chondrodystrophic myotonia and is a rare syndrome combining skeletal abnormalities (short stature, multiple epiphyseal dysplasia, joint contractures, characteristic facies) with muscle stiffness. Its molecular cause was identified by Nicole et al. in 2001 as variants of the HSPG2 gene (encoding the protein perlecan). Symptomatic myotonia is myotonia secondarily induced by drugs such as statins, clofibrate and cholestyramine, electrolyte abnormalities, hypothyroidism, etc., and was gradually recognized as pharmacoepidemiology developed. Pseudomyotonia refers to a condition clinically similar to myotonia but without true myotonic discharges on EMG, and must be differentiated from rippling muscle disease or neuromyotonia.

2. Causes

Other myotonic disorders are broadly classified into three groups by cause.

Schwartz-Jampel syndrome (chondrodystrophic myotonia)

Symptomatic myotonia (drug or metabolic causes)

Pseudomyotonia

3. Genetics

Schwartz-Jampel syndrome

Autosomal recessive inheritance. Biallelic pathogenic variants of the HSPG2 gene (1p36.1). Various types, including deletion, missense, nonsense and splicing variants, have been reported. Incidence is higher in consanguineous families. Some genotype-phenotype correlation exists, and complete loss-of-function variants may present a more severe phenotype (SJS type 1B or the lethal form).

Symptomatic myotonia and pseudomyotonia

When not a genetic disease (drug or metabolic causes), genetic classification does not apply. However, there are reports that an underlying genetic predisposition (e.g., CLCN1 carrier status) can increase the risk of developing drug-induced myotonia. Brody disease is an autosomal recessive genetic disease caused by ATP2A1 gene variants.

DiseaseGeneMode of inheritanceKey features
Schwartz-Jampel syndromeHSPG2Autosomal recessiveSkeletal abnormalities + myotonia
Brody diseaseATP2A1Autosomal recessiveDelayed relaxation after exercise, normal EMG
Symptomatic myotoniaNot applicableAcquiredDrug or metabolic causes
Hypothyroidism-relatedNot applicableAcquiredRecovers with thyroid treatment

4. General epidemiology

Because other myotonic disorders are a heterogeneous group, it is difficult to express the overall prevalence as a single figure. Schwartz-Jampel syndrome is so rare that fewer than several hundred cases have been reported worldwide. Prevalence is equal between sexes, and it is reported relatively more often in regions where consanguineous marriage is frequent, such as the Middle East and India. Awareness of symptomatic (drug-induced) myotonia is increasing in clinical practice as statin prescriptions increase, but overall prevalence is low. While the incidence of statin-induced myopathy is high at about 10%, the proportion accompanied by myotonic discharges is much lower. Hypothyroidism-related myotonia (Hoffmann syndrome) is very rare relative to the prevalence of hypothyroidism itself.

5. Pathophysiology

Pathogenesis of Schwartz-Jampel syndrome

Perlecan, encoded by the HSPG2 gene, is a heparan sulfate proteoglycan of the extracellular matrix (ECM) and a component of the basement membrane of the neuromuscular junction (NMJ). Perlecan anchors acetylcholinesterase (AChE) at the NMJ. With HSPG2 loss-of-function variants, AChE is not normally anchored at the NMJ, resulting in excessive accumulation of acetylcholine and thereby continuous muscle activity. At the same time, abnormal basement membrane composition in cartilage and bone results in skeletal dysplasia.

Pathogenesis of symptomatic myotonia

Pathogenesis of pseudomyotonia

6. Symptoms

Schwartz-Jampel syndrome

Symptomatic myotonia (statin-induced)

Hypothyroidism-related (Hoffmann syndrome)

Pseudomyotonia (Brody disease)

7. Signs

Schwartz-Jampel syndrome

Symptomatic myotonia

Pseudomyotonia (Brody disease)

Common laboratory findings

8. Screening

9. Diagnosis

Schwartz-Jampel syndrome

Symptomatic myotonia and metabolic causes

Pseudomyotonia (Brody disease)

Summary of differential diagnosis

DiseaseEMGwarm-upSkeletal abnormalitiesConfirmation
Schwartz-Jampel syndromeMyotonic discharges + continuous motor unit activityNonePresentHSPG2
Brody diseaseElectrical silencePresentNoneATP2A1
Symptomatic (statin)Myotonic discharges (mild)PossibleNoneResolves after drug discontinuation
HypothyroidismMyotonic discharges possiblePossibleNoneTSH↑, FT4↓

10. Treatment

Schwartz-Jampel syndrome

Symptomatic (drug-induced) myotonia

Hypothyroidism-related

Pseudomyotonia (Brody disease)

11. Prognosis

The prognosis of other myotonic disorders differs greatly by underlying disease. Schwartz-Jampel syndrome is nonprogressive, but functional limitation and complications due to skeletal abnormalities (progression of scoliosis, reduced respiratory function) can be long-term problems. Function can be maintained with appropriate orthopedic intervention and rehabilitation. Most patients have a normal or near-normal lifespan, but the prognosis may become poor with severe skeletal abnormalities or respiratory complications. Symptomatic (drug-induced) myotonia mostly recovers completely after discontinuation of the causative drug, and the prognosis is good. Hypothyroidism-related myotonia is also expected to recover completely with appropriate hormone replacement. Brody disease (pseudomyotonia) is not progressive and has no life-threatening complications, so the prognosis is good, but limited exercise capacity can affect quality of life.

12. Prevention

13. References

  1. Nicole S, Davoine CS, Topaloglu H, et al. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet. 2000;26(4):480–483. PMID: 11101850
  2. Aberfeld DC, Hinterbuchner LP, Schneider M. Myotonia, dwarfism, diffuse bone disease and unusual ocular and facial abnormalities (a new syndrome). Brain. 1965;88(2):313–322. PMID: 5828997
  3. Doriguzzi C, Palmucci L, Mongini T, Chiado-Piat L, Maniscalco M. Schwartz-Jampel syndrome: a new variant (type II). Eur Neurol. 1993;33(1):63–68. PMID: 8422819
  4. Rajpal MK, Sedki FK, Eid TJ. Statin-induced myopathy in a patient with Schwartz-Jampel syndrome. J Pharm Pract. 2024;37(1):227–230. PMID: 37931642
  5. Quane KA, Healy JM, Keating KE, et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet. 1993;5(1):51–55. PMID: 8220423
  6. Brody IA. Muscle contracture induced by exercise. A syndrome attributable to decreased relaxing factor. N Engl J Med. 1969;281(4):187–192. PMID: 4308552
  7. Taylor RG, Layzer RB, Davis HS, Fowler WM Jr. Continuous muscle fiber activity in the Schwartz-Jampel syndrome. Electroencephalogr Clin Neurophysiol. 1972;33(5):497–509. PMID: 4117558
  8. Paganoni S, Amato A. Electrodiagnostic evaluation of myopathies. Phys Med Rehabil Clin N Am. 2013;24(1):193–207. PMID: 23177040
  9. Statland JM, Barohn RJ, Dimachkie MM, Floeter MK, Trivedi JR. Nondystrophic myotonias. Neurol Clin. 2014;32(3):801–815. PMID: 25037089
  10. Fialho D, Bhatt DL, Hanna MG, Hanna MG. Non-dystrophic myotonias: a consensus guide to diagnosis and management. Pract Neurol. 2018;18(6):484–498. PMID: 29959219